This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Raghav Gulati and Ananyaa Sood shine at the Tommy Fleetwood International Pathway Series at Yas Links Abu Dhabi, securing top ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today ...

Raghav Gulati takes a one-shot lead with an impressive five-under-par 67 on Day One of the Tommy Fleetwood Pathway Series at ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial position.

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

The R&A has announced the qualification pathways for The 153rd Open at Royal Portrush, taking place July 13-20, 2025. The ...

Thus, we will focus primarily on the therapeutic targeting of the major RAS effector pathways, in addition to several essential co-opted pathways, as reviewed in the next section. MEK/CDK4 PD ...

Seated L -R : H.E. Martina Strong, US Ambassador to the UAE, His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, H.E. Edward Hobart, UK Ambassador to ...

Six Democratic candidates vying for New Jersey’s governorship spoke directly to voters at the first debate of the season ...